CARCLO PLC

Pre-Annual General Meeting Information • Feb 9, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3426E

Carclo plc

09 February 2015

For immediate release                                                                         

9 February 2015

Carclo plc

("Carclo" or the "Group")

Notice of General Meeting

Following the announcement made on 5 February 2015 as part of the interim management statement, Carclo plc (the Company) announces that it has today issued a circular to shareholders to convene a general meeting of the Company to be held at 3.30 p.m. on 25 February 2015 at the Company's registered office, to seek shareholder approval for the cancellation of the Company's share premium account and capital redemption reserve.

The board of directors of the Company is recommending the cancellations (which, if shareholder approval is obtained, will also need to be confirmed by the High Court of Justice in England and Wales) in order to augment the Company's distributable reserves and therefore allow the Company to have access to sufficient distributable reserves to, amongst other matters, enable future dividends to be paid as and when the Board considers it appropriate.

The reasons for, background to, and a summary of the court process relating to the cancellations are set out in full in the circular and a copy of the circular is available on the Company's web site at www.carclo-plc.com

- ENDS -

Enquiries:

Carclo plc		01924 268040
Chris Malley, Chief Executive
Robert Brooksbank, Finance Director
Peel Hunt LLP		0207 418 8900
Justin Jones
Jock Maxwell Macdonald
Mike Bell
N+1 Singer Shaun Dobson Richard Lindley		0207 496 3000
Weber Shandwick Nick Oborne Tom Jenkins		0207 067 0000

Notes to editors

Carclo plc is a public company whose shares are quoted on the London Stock Exchange.

Carclo's strategy is to develop and expand its key manufacturing assets where there remain significant further opportunities to drive value. To enhance profit margins the group has been investing in new technologies.

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, mainly for medical products. The balance of revenue is derived mainly from the design and supply of specialised injection moulded LED based lighting systems to the low volume premium automotive industry.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDQLFBELFFBBE